ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
会议论文

Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagnosed advanced ovarian cancer (aOC)

Zhu, Jianqing; Wu, Lingying; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jilong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhang, Yu; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei复旦大学; 北京大学; 华中科技大学; 山东大学; 哈尔滨医科大学; 四川大学; 浙江大学; 郑州大学; 中国医学科学院; 中山大学; 重庆大学; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
2023-9DOI: 10.1016/j.ygyno.2023.06.175
2阅读
引用收藏
分享
相关
加载中…
  • Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
    Li, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Wu, Lingying被引 21
  • Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, placebo-controlled, phase 3 trial
    Li, Ning; Zhu, Jianqing; Yin, Rutie; Wang, Jing; Pan, Lingya; Kong, Beihua; Zheng, Hong; Liu, Jihong; Wu, Xiaohua; Wang, Li; Huang, Yi; Wang, Ke; Zou, Dongling; Zhao, Hongqin; Wang, Chunyan; Lu, Weiguo; Lin, An; Lou, Ge; Li, Guiling; Qu, Pengpeng; Yang, Hongying; Zhen, Xiaoa; Hang, Wenzhao; Hou, Jianmei; Banerjee, Ashish; Wu, Lingying
  • First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
    Li, J.; Youguo, C.; Mian, H.; Chen, X.; Wen, H.; Kang, Y.; Liu, K. J.; Lou, G.; Wang, X.; Wen, Q. L.; Wang, L.; Lin, Z.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
查看全部 →

会议信息

论文集名
GYNECOLOGIC ONCOLOGY
发表日期
2023-09
起止页码
S168-S169
DOI
10.1016/j.ygyno.2023.06.175
收录
SCIE

作者

  • Z

    Zhu, Jianqing (第一作者)

    univ chinese acad sci · zhejiang canc hosp

  • W

    Wu, Lingying

查看全部 25 位作者收起作者
  • Y

    Yin, Rutie

    2 · sichuan univ

  • W

    Wang, Jing

    hunan canc hosp

  • P

    Pan, Lingya

    chinese acad med sci · peking union med coll hosp

  • K

    Kong, Beihua

    shandong univ

  • Z

    Zheng, Hong

    peking univ

  • L

    Liu, Jilong

    sun yat sen univ

  • W

    Wu, Xiaohua

    fudan univ

  • W

    Wang, Li

    zhengzhou univ

  • H

    Huang, Yi

    hubei canc hosp

  • W

    Wang, Ke

    tianjin med univ

  • Z

    Zou, Dongling

    chongqing univ

  • Z

    Zhao, Hongqin

    1 · wenzhou med univ

  • W

    Wang, Chunyan

    liaoning canc hosp

  • L

    Lu, Weiguo

    zhejiang univ

  • L

    Lin, An

    fujian canc hosp · fujian med univ

  • L

    Lou, Ge

    harbin med univ

  • L

    Li, Guiling

    huazhong univ sci & technol

  • Q

    Qu, Pengpeng

  • Y

    Yang, Hongying

  • Z

    Zhang, Yu

  • Z

    Zhen, Xiaoa

  • H

    Hang, Wenzhao

  • H

    Hou, Jianmei

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417